{"entity":{"type":"insider","cik":"0001293789","url":"/insider/0001293789","json_url":"/insider/0001293789.json","name":"Steinhart Richard I","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":16,"n_filings":15,"first":"2010-08-12","last":"2026-05-22","span_basis":"filed_date"},"name_variants":[{"name":"Steinhart Richard I","source":"filing","n_filings":15,"first_seen":"2010-08-12","last_seen":"2026-05-22"}],"transactions":[{"id":6226719,"accession":"0001104659-26-065838","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-26-065838","line_url":"/filing/0001104659-26-065838#line-2","is_derivative":false,"issuer_cik":"0001293789","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001293789","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6845.0,"shares_display":"6,845","price_per_share":1.085,"price_display":"1.08","price_state":"stated","total_value":7426.825,"total_display":"7,426.82","total_whole":"7,427","shares_owned_after":26300.0,"shares_owned_after_display":"26,300","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-20","filed_date":"2026-05-22","scope":"insider"},{"id":2373187,"accession":"0001104659-24-129461","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-24-129461","line_url":"/filing/0001104659-24-129461","is_derivative":false,"issuer_cik":"0001293789","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001293789","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":577.0,"shares_display":"577","price_per_share":0.3587105719237435,"price_display":"0.36","price_state":"stated","total_value":206.976,"total_display":"206.98","total_whole":"207","shares_owned_after":20932.0,"shares_owned_after_display":"20,932","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-16","filed_date":"2024-12-17","scope":"insider","n_lines":2},{"id":3118364,"accession":"0001104659-24-106061","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-106061","line_url":"/filing/0001104659-24-106061#line-2","is_derivative":false,"issuer_cik":"0001293789","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001293789","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7175.0,"shares_display":"7,175","price_per_share":0.55,"price_display":"0.55","price_state":"stated","total_value":3946.25,"total_display":"3,946.25","total_whole":"3,946","shares_owned_after":20279.0,"shares_owned_after_display":"20,279","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-03","filed_date":"2024-10-03","scope":"insider"},{"id":3067449,"accession":"0001104659-24-100749","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-24-100749","line_url":"/filing/0001104659-24-100749#line-3","is_derivative":false,"issuer_cik":"0001293789","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001293789","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":356.0,"shares_display":"356","price_per_share":0.6899,"price_display":"0.69","price_state":"stated","total_value":245.6044,"total_display":"245.60","total_whole":"246","shares_owned_after":6204.0,"shares_owned_after_display":"6,204","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-16","filed_date":"2024-09-17","scope":"insider"},{"id":2875576,"accession":"0001104659-24-073002","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-24-073002","line_url":"/filing/0001104659-24-073002#line-3","is_derivative":false,"issuer_cik":"0001293789","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001293789","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":372.0,"shares_display":"372","price_per_share":1.2622,"price_display":"1.26","price_state":"stated","total_value":469.5384,"total_display":"469.54","total_whole":"470","shares_owned_after":5476.0,"shares_owned_after_display":"5,476","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-17","filed_date":"2024-06-18","scope":"insider"},{"id":2529148,"accession":"0001104659-24-044860","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-24-044860","line_url":"/filing/0001104659-24-044860#line-3","is_derivative":false,"issuer_cik":"0001293789","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001293789","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1069.0,"shares_display":"1,069","price_per_share":2.635,"price_display":"2.64","price_state":"stated","total_value":2816.815,"total_display":"2,816.82","total_whole":"2,817","shares_owned_after":4765.0,"shares_owned_after_display":"4,765","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-04","filed_date":"2024-04-08","scope":"insider"},{"id":7803804,"accession":"0001104659-23-061538","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-23-061538","line_url":"/filing/0001104659-23-061538#line-2","is_derivative":false,"issuer_cik":"0001293789","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001293789","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":27.1727,"price_display":"27.17","price_state":"stated","total_value":135863.5,"total_display":"135,863.50","total_whole":"135,864","shares_owned_after":1500.0,"shares_owned_after_display":"1,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-15","filed_date":"2023-05-16","scope":"insider"},{"id":7803591,"accession":"0001104659-23-033408","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-23-033408","line_url":"/filing/0001104659-23-033408#line-2","is_derivative":false,"issuer_cik":"0001293789","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001293789","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2084.0,"shares_display":"2,084","price_per_share":19.5,"price_display":"19.50","price_state":"stated","total_value":40638.0,"total_display":"40,638.00","total_whole":"40,638","shares_owned_after":1500.0,"shares_owned_after_display":"1,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-15","filed_date":"2023-03-16","scope":"insider"},{"id":4947669,"accession":"0001104659-21-011542","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-21-011542","line_url":"/filing/0001104659-21-011542#line-2","is_derivative":false,"issuer_cik":"0001293789","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001293789","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3750.0,"shares_display":"3,750","price_per_share":48.15,"price_display":"48.15","price_state":"stated","total_value":180562.5,"total_display":"180,562.50","total_whole":"180,563","shares_owned_after":1500.0,"shares_owned_after_display":"1,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-01","filed_date":"2021-02-03","scope":"insider"},{"id":6221305,"accession":"0001104659-18-071215","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-18-071215","line_url":"/filing/0001104659-18-071215#line-1","is_derivative":false,"issuer_cik":"0001293789","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001293789","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":5.1999,"price_display":"5.20","price_state":"stated","total_value":2599.95,"total_display":"2,599.95","total_whole":"2,600","shares_owned_after":1500.0,"shares_owned_after_display":"1,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-03","filed_date":"2018-12-04","scope":"insider"},{"id":6572601,"accession":"0001104659-18-070876","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-18-070876","line_url":"/filing/0001104659-18-070876#line-1","is_derivative":false,"issuer_cik":"0001293789","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001293789","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":2500.0,"total_display":"2,500.00","total_whole":"2,500","shares_owned_after":1000.0,"shares_owned_after_display":"1,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-30","filed_date":"2018-11-30","scope":"insider"},{"id":6681524,"accession":"0001104659-18-070793","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-18-070793","line_url":"/filing/0001104659-18-070793#line-1","is_derivative":false,"issuer_cik":"0001293789","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001293789","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":2500.0,"total_display":"2,500.00","total_whole":"2,500","shares_owned_after":500.0,"shares_owned_after_display":"500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-29","filed_date":"2018-11-30","scope":"insider"},{"id":2182097,"accession":"0001213900-16-012631","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-16-012631","line_url":"/filing/0001213900-16-012631#line-1","is_derivative":false,"issuer_cik":"0001293789","issuer_name":"Actinium Pharmaceuticals, Inc.","issuer_ticker":"ATNM","issuer_name_source":null,"issuer_url":"/issuer/0001293789","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500.0,"shares_display":"2,500","price_per_share":2.01,"price_display":"2.01","price_state":"stated","total_value":5025.0,"total_display":"5,025.00","total_whole":"5,025","shares_owned_after":2500.0,"shares_owned_after_display":"2,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-04-14","filed_date":"2016-04-18","scope":"insider"},{"id":4424780,"accession":"0001209191-13-033488","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-13-033488","line_url":"/filing/0001209191-13-033488#line-1","is_derivative":false,"issuer_cik":"0001051514","issuer_name":"MELA SCIENCES, INC. /NY","issuer_ticker":"MELA","issuer_name_source":null,"issuer_url":"/issuer/0001051514","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000.0,"shares_display":"3,000","price_per_share":0.809,"price_display":"0.81","price_state":"stated","total_value":2427.0,"total_display":"2,427.00","total_whole":"2,427","shares_owned_after":4000.0,"shares_owned_after_display":"4,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-06-25","filed_date":"2013-06-25","scope":"insider"},{"id":7515552,"accession":"0001209191-10-042316","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-10-042316","line_url":"/filing/0001209191-10-042316#line-1","is_derivative":false,"issuer_cik":"0001051514","issuer_name":"MELA SCIENCES, INC. /NY","issuer_ticker":"MELA","issuer_name_source":null,"issuer_url":"/issuer/0001051514","owner_cik":"0001293789","owner_name":"Steinhart Richard I","owner_display_name":"Steinhart Richard I","owner_url":"/insider/0001293789","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":6.32,"price_display":"6.32","price_state":"stated","total_value":6320.0,"total_display":"6,320.00","total_whole":"6,320","shares_owned_after":1000.0,"shares_owned_after_display":"1,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-08-12","filed_date":"2010-08-12","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":16,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":6,"open_market":true},{"code":"S","label":"Open-market sale","n":10,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":16},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001720893","name":"BioXcel Therapeutics, Inc.","url":"/issuer/0001720893","role":"Officer (Chief Financial Officer)","n_filings":12,"first_seen":"2018-11-30","last_seen":"2026-05-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001388320","name":"Actinium Pharmaceuticals, Inc.","url":"/issuer/0001388320","role":"Director","n_filings":1,"first_seen":"2016-04-18","last_seen":"2016-04-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001051514","name":"MELA SCIENCES, INC. /NY","url":"/issuer/0001051514","role":"Officer (Chief Financial Officer)","n_filings":2,"first_seen":"2010-08-12","last_seen":"2013-06-25"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001293789","retrieved_at":"2026-08-25T19:27:54+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}